Molecular Markers Laboratory, IRCCS Istituto Centro San Giovanni di Dio Fatebenefratelli, 25125 Brescia, Italy.
Fatebenefratelli Foundation for Health Research and Education, AFaR Division, San Giovanni Calibita Fatebenefratelli Hospital, Isola Tiberina, 00186 Rome, Italy.
Biomolecules. 2021 Jun 29;11(7):960. doi: 10.3390/biom11070960.
Evidence indicates that patients with Alzheimer's dementia (AD) show signs of copper (Cu) dyshomeostasis. This study aimed at evaluating the potential of Cu dysregulation as an AD susceptibility factor. We performed a meta-analysis of 56 studies investigating Cu biomarkers in brain specimens (pooled total of 182 AD and 166 healthy controls, HC) and in serum/plasma (pooled total of 2929 AD and 3547 HC). We also completed a replication study of serum Cu biomarkers in 97 AD patients and 70 HC screened for rs732774 and rs1061472 , the gene encoding for the Cu transporter ATPase7B. Our meta-analysis showed decreased Cu in AD brain specimens, increased Cu and nonbound ceruloplasmin (Non-Cp) Cu in serum/plasma samples, and unchanged ceruloplasmin. Serum/plasma Cu excess was associated with a three to fourfold increase in the risk of having AD. Our replication study confirmed meta-analysis results and showed that carriers of the AG haplotype were significantly more frequent in the AD group. Overall, our study shows that AD patients fail to maintain a Cu metabolic balance and reveals the presence of a percentage of AD patients carrying AG haplotype and presenting Non-Cp Cu excess, which suggest that a subset of AD subjects is prone to Cu imbalance. This AD subtype can be the target of precision medicine-based strategies tackling Cu dysregulation.
证据表明,阿尔茨海默病(AD)患者存在铜(Cu)稳态失调的迹象。本研究旨在评估 Cu 调节异常作为 AD 易感性因素的潜在作用。我们对 56 项研究进行了荟萃分析,这些研究调查了脑标本中的 Cu 生物标志物(共纳入 182 例 AD 和 166 例健康对照者,HC)和血清/血浆中的 Cu 生物标志物(共纳入 2929 例 AD 和 3547 例 HC)。我们还对 97 例 AD 患者和 70 例筛查 rs732774 和 rs1061472(编码 Cu 转运体 ATPase7B 的基因)的 HC 进行了血清 Cu 生物标志物的复制研究。我们的荟萃分析显示 AD 脑标本中的 Cu 减少,血清/血浆样本中的 Cu 和非结合铜蓝蛋白(Non-Cp)Cu 增加,而铜蓝蛋白不变。血清/血浆 Cu 过剩与 AD 风险增加三至四倍相关。我们的复制研究证实了荟萃分析的结果,并显示携带 AG 单倍型的患者在 AD 组中更为常见。总体而言,我们的研究表明 AD 患者无法维持 Cu 代谢平衡,并揭示了存在一定比例的携带 AG 单倍型和表现出 Non-Cp Cu 过剩的 AD 患者,这表明 AD 患者亚群容易发生 Cu 失衡。这种 AD 亚型可能是基于精准医学的策略治疗 Cu 失调的目标。